1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan; 2. Department of Medicine, Numazu City Hospital, Numazu, Shizuoka, Japan; 3. Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
✉ Corresponding author: Tetsuhiro Chiba, M.D., Ph.D. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. Telephone: +81-43-2262083 Fax: +81-43-2262088 E-mail: techibachiba-u.jp.More
Citation:
Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N, Motoyama T, Ogasawara S, Ooka Y, Tawada A, Kanda T, Miyazaki M, Yokosuka O. Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. Int J Med Sci 2014; 11(7):707-712. doi:10.7150/ijms.8764. https://www.medsci.org/v11p0707.htm
Previous reports have shown that interferon (IFN)-based therapy decreases the risk of development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection. However, it remains to be fully elucidated whether elimination of HCV by IFN-based therapy inhibits HCC recurrence after curative treatment, such as surgical resection and local ablation therapies. In this study, we aimed to clarify the influence of a sustained virological response (SVR) after IFN-based therapy on recurrence and survival after curative treatment of HCC. Fifty-one patients who underwent curative treatment of HCV-related HCC after receiving IFN-based therapy were analyzed retrospectively. They were classified into SVR (N = 14) and non-SVR groups (N = 37). In the SVR group, serum levels of aspartate aminotransferase and alanine aminotransferase, the indocyanine green retention rate at 15 min, and the percentages of patients with liver cirrhosis and HCV serotype 1 were significantly lower, whereas serum albumin level and platelet count were significantly higher upon HCC occurrence. Recurrence-free survival (RFS) for the first recurrence was significantly higher in the SVR group (P < 0.01). Multivariate analysis showed that SVR at initial HCC treatment (P < 0.01) and multiple tumors (P < 0.01) are prognostic factors for RFS. Moreover, RFS for the second recurrence showed a similar trend to that for the first recurrence. In conclusion, patients who underwent IFN-based therapy before initial curative treatment of HCC had a favorable clinical outcome compared with non-SVR patients.
Keywords: HCC, HCV, IFN, recurrence, SVR.
Citation styles
APA
Saito, T., Chiba, T., Suzuki, E., Shinozaki, M., Goto, N., Kanogawa, N., Motoyama, T., Ogasawara, S., Ooka, Y., Tawada, A., Kanda, T., Miyazaki, M., Yokosuka, O. (2014). Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. International Journal of Medical Sciences, 11(7), 707-712. https://doi.org/10.7150/ijms.8764.
ACS
Saito, T.; Chiba, T.; Suzuki, E.; Shinozaki, M.; Goto, N.; Kanogawa, N.; Motoyama, T.; Ogasawara, S.; Ooka, Y.; Tawada, A.; Kanda, T.; Miyazaki, M.; Yokosuka, O. Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. Int. J. Med. Sci. 2014, 11 (7), 707-712. DOI: 10.7150/ijms.8764.
NLM
Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N, Motoyama T, Ogasawara S, Ooka Y, Tawada A, Kanda T, Miyazaki M, Yokosuka O. Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. Int J Med Sci 2014; 11(7):707-712. doi:10.7150/ijms.8764. https://www.medsci.org/v11p0707.htm
CSE
Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N, Motoyama T, Ogasawara S, Ooka Y, Tawada A, Kanda T, Miyazaki M, Yokosuka O. 2014. Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. Int J Med Sci. 11(7):707-712.